Ashland FY 2026: sales up 2%, net income back in the black
Ashland reported fiscal 2026 revenue of $1.86 billion and net income of $4 million versus a prior-year loss, and outlined its fiscal 2027 forecast.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Ashland's fiscal 2026 revenue reached $1.86 billion, up from $1.82 billion a year earlier, an increase of 2.1%. Net income came in at $4 million, compared with a loss of $845 million in the prior year. Diluted earnings per share were $0.09, against a loss of $18.23 per share.
The company attributed the sales gain to higher volume and favorable currency exchange, which were partly offset by unfavorable price/mix and the sale of Avoca. The Life Sciences segment lifted adjusted EBITDA by $12 million to $205 million, while Specialty Additives saw its figure fall by $24 million to $70 million.
For fiscal 2027, the company expects sales between $1,905 million and $1,975 million, growth of roughly 2% to 6%, and adjusted EBITDA of $405 million to $435 million. These figures come from a TradingView summary based on documents filed with the SEC, which notes that it is AI-generated and may contain inaccuracies.
why it matters
For markets, this is a single chemicals company's report, but it shows profit returning to positive territory after last year's goodwill impairment. Investors typically focus on segment adjusted EBITDA trends and the outlook, since that sets expectations for earnings in the coming year.
market impact
Ashland shares: return to profit, with attention on the forecast and segment trends
tags
instruments
sources
- Ashland FY 2026: Revenue $1.86B, EPS $0.09 — 10-K Summary — TradingView, 20 November 2026 at 17:25 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗